The Herceptin Adjuvant ( HERA ) trial is a three-arm , randomized trial comparing 2 years or 1 year of trastuzumab with observation in 5,102 patients with human epidermal growth factor receptor 2 ( HER2 ) - positive early-stage breast cancer .